{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lu-177-DOTATATE&page=2",
    "query": {
      "intervention": "Lu-177-DOTATATE",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lu-177-DOTATATE&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lu-177-DOTATATE&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T11:01:23.406Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06784752",
      "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Somatostatin Receptor Positive (SSTR+)",
        "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "RADIATION"
        },
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 240,
      "start_date": "2025-05-30",
      "completion_date": "2034-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784752"
    },
    {
      "nct_id": "NCT03206060",
      "title": "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pheochromocytoma",
        "Paraganglioma",
        "Neuroendocrine Tumors",
        "Neuroendocrine Neoplasms"
      ],
      "interventions": [
        {
          "name": "Lu-177-DOTATATE",
          "type": "DRUG"
        },
        {
          "name": "Ga-68-DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 130,
      "start_date": "2017-10-10",
      "completion_date": "2033-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03206060"
    },
    {
      "nct_id": "NCT05249114",
      "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Lu-177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-12-28",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05249114"
    },
    {
      "nct_id": "NCT05278208",
      "title": "Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Meningioma",
        "Embryonal Tumor",
        "Medulloblastoma",
        "Anaplastic Ependymoma",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Malignant Glioma",
        "Recurrent Medulloblastoma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Refractory Diffuse Intrinsic Pontine Glioma",
        "Refractory Malignant Glioma",
        "Refractory Medulloblastoma",
        "Refractory Primary Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "LUTATHERA® (Lutetium Lu 177 dotatate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "4 Years to 39 Years"
      },
      "enrollment_count": 65,
      "start_date": "2022-11-21",
      "completion_date": "2033-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05278208"
    },
    {
      "nct_id": "NCT04082520",
      "title": "Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade 1 Meningioma",
        "Grade 2 Meningioma",
        "Grade 3 Meningioma",
        "Recurrent Meningioma",
        "Unresectable Meningioma"
      ],
      "interventions": [
        {
          "name": "Gallium Ga 68-DOTATATE",
          "type": "RADIATION"
        },
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2020-04-14",
      "completion_date": "2032-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04082520"
    },
    {
      "nct_id": "NCT03923257",
      "title": "Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Pheochromocytoma",
        "Paraganglioma"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTA-tyr3-OCTREOTATE",
          "type": "DRUG"
        },
        {
          "name": "Peptide Receptor Radiotherapy (PRRT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sue O'Dorisio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "1 Year to 20 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-08-04",
      "completion_date": "2021-06-03",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923257"
    },
    {
      "nct_id": "NCT06663072",
      "title": "Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-12-13",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06663072"
    },
    {
      "nct_id": "NCT05583708",
      "title": "Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lutetium Lu 177 dotatate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-08-03",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Iowa City, Iowa • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05583708"
    },
    {
      "nct_id": "NCT05816720",
      "title": "Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Lutetium-177 DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-09-01",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05816720"
    },
    {
      "nct_id": "NCT03457948",
      "title": "Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Liver",
        "Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Arterial Embolization",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yttrium-90 Microsphere Radioembolization",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Nicholas Fidelman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-08-27",
      "completion_date": "2026-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-30T11:01:23.406Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03457948"
    }
  ]
}